DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast - 2023 - EU5" drug pipelines to their offering.
This report provides an overview of the disease and market size of the CMV for the EU5 (France, Germany, Italy, Spain and United Kingdom) for 2013 - 2023. It also includes historical and forecast edepidemiological data for the CMV Prevalent, Diagnosed and Treatable Cases, CMV Patients among Transplants, Infants Patients at High Risk of CMV and HIV Patients at High Risk of CMV from 2013 - 2023.
According to experts, the total number of Diagnosed Cytomegalovirus (CMV) infection cases in France is expected to increase at a CAGR of 0.06% to 20,871 cases by 2023. In case of Germany it is expected to increase at a CAGR of 0.067% to 21,619 cases by 2023. In United Kingdom, the total number of Diagnosed Cytomegalovirus (CMV) infection cases is expected to increase at a CAGR of 0.061% to 14,417 cases by 2023 and in Spain is expected to increase at a CAGR of 0.029% to 12,810 cases in 2023. For Italy, it is expected to increase at a CAGR of 0.031% to 13,358 cases in 2023. CMV infection is most prevalent in Italy and least prevalent in Spain of the EU5.
As per our estimation, the market size of Cytomegalovirus (CMV) infection shall reach to USD 50.2 Million in Italy, USD 213.3 Million in Germany, USD 142.3 Million in France, USD 62.8 Million in Spain and USD 63.8 Million in United Kingdom by the end of 2023. Italy has the lowest and Germany has the highest market size of the EU5.
Marketed Products
- Valcyte (Valganciclovir hydrochloride)
- FOSCAVIR (foscarnet sodium)
- CytoGam (Cytomegalovirus Immune Globulin Intravenous-Human)
- CytoTect CP
- Valtrex (Valacyclovir hydrochloride)
Emerging Therapies
- Cytovir CMV: Cell Medica Ltd.
- CytoTect CP 70: Biotest AG.
- Letermovir: Merck & Co.
- Brincidofovir: Chimerix Inc.
- ASP0113: Astellas Pharma Global Development, Inc.
- Human Cytomegalovirus Immune Globulin: CSL Behring
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/cc54xp/cytomegalovirus
